Success Stories
Highlights of the PCI news focused on Penn commercialization accomplishments
Highlights of the PCI news focused on Penn commercialization accomplishments
Mike Mitchell's lab has numerous ongoing research partnerships to support new therapeutic solutions with commercial entities that were facilitated by PCI.
Penn and Carisma Therapeutics (Carisma) have strengthened the intellectual property portfolio covering this technology with the issuance of five additional patents in 2022.
Read about how this Philadelphia-based agricultural biotech startup received funding from Mark Cuban, Google Ventures, and others.
Fiscal year 2022 saw the Co-Investment Program help launch and fund 2 new companies ViTToria Biotherapeutics and Dispatch Bio, as well as participate in follow-on rounds for Linnaeus Therapeutics, Car
Read about how May graduates won the 2022 President's Sustainability Prize for their device that reduces microplastic pollution.
Vittoria Biotherapeutics' mission is to overcome current limitations of chimeric antigen receptor (CAR) T-cell therapeutics by using its unique cell engineering and gene editing technologies.
From May 6 - 12, PCI participated in the 12th annual Philly Tech Week, a conference hosted by Technical.ly Philly, to showcase some of the city's best technology and innovation.
Abrax Japan entered into an exclusive licensing agreement for certain Penn-owned inventions relating to the therapeutic effects of thymic stromal lymphopoietin (TSLP).
Awarded annually, the President’s Innovation Prize empowers Penn students to design and undertake a post-graduation startup company that makes a positive, lasting difference in the world.
Penn Engineering’s newly formed ASSET (AI-enabled Systems: Safety, Explainablity and Trustworthiness) Center is part of Penn Engineering’s Innovation in Data Engineering & Science (IDEAS) Initiative.